Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database

QR Code

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database

This study evaluated adverse events reported with tirzepatide, a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and obesity, using real-world data from the FDA Adverse Event Reporting System. A disproportionality analysis was conducted on reports from May 2022 to the fourth quarter of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zhenpo Zhang, Jiangxiong Li, Jingping Zheng, Yankun Liang, Lin Ma, Ling Su
Format:	Article
Language:	English
Published:	Bioscientifica 2025-07-01
Series:	Endocrine Connections
Subjects:	tirzepatide type 2 diabetes pharmacovigilance faers database adverse drug events real-world evidence
Online Access:	https://ec.bioscientifica.com/view/journals/ec/14/7/EC-25-0205.xml
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database
by: Zhifang Wang, et al.
Published: (2025-07-01)

Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-12-01)

A real-world pharmacovigilance study of lorazepam based on the FDA adverse event reporting system database
by: Chunyue Fang, et al.
Published: (2025-06-01)

Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) database
by: Huiling Zhang, et al.
Published: (2025-07-01)

Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database
by: Juan Su, et al.
Published: (2025-07-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Identification of potential drug-induced neuralgia signals through disproportionality analysis of the FAERS database
by: Yating An, et al.
Published: (2025-07-01)

Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system
by: Qian Yu, et al.
Published: (2025-08-01)

Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
by: Xiang Li, et al.
Published: (2025-06-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Xinzhen Che, et al.
Published: (2025-06-01)

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database
by: JunYun Luo, et al.
Published: (2025-12-01)

Signal mining and risk analysis of olanzapine adverse events in the FAERS database
by: Aiguo Dong, et al.
Published: (2025-07-01)

Drug-associated hearing impairment in children: a disproportionality analysis of the FDA adverse event reporting system
by: Jinfeng Liu, et al.
Published: (2025-06-01)

Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system
by: Nan Chen, et al.
Published: (2025-06-01)

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
by: Xiaomeng Di, et al.
Published: (2025-07-01)

Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System
by: Yi Zhang, et al.
Published: (2025-07-01)

Potential adverse events of fluoxetine: a real-world study based on the FAERS database
by: Xuezheng Gao, et al.
Published: (2025-07-01)

Evaluating Triptan Safety in Pediatric Migraine Management: A Comprehensive Pharmacovigilance Analysis
by: Chen J, et al.
Published: (2025-06-01)

A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide
by: Mengmeng Huang, et al.
Published: (2025-07-01)

Exploring Ototoxicity Associated with Capmatinib: Insights from a Real-World Data Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Lin Y, et al.
Published: (2025-06-01)

Mifepristone-related foetal cardiac adverse events: findings from the postmarketing safety reports
by: Ran Liu, et al.
Published: (2025-12-01)

Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis
by: Qiru Tian, et al.
Published: (2025-07-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Evaluating the risk of osteoporosis-related adverse events with proton pump inhibitors: a pharmacovigilance study
by: Jingkai Di, et al.
Published: (2025-07-01)

Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis
by: Qian Wang, et al.
Published: (2025-06-01)

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines
by: Matthew Halma, et al.
Published: (2025-03-01)

Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database
by: Chao Tao, et al.
Published: (2025-07-01)

ADVERSE EVENTS OF INTERFERONS WITH SYSTEMIC EFFECT
by: A. A. Toporov, et al.
Published: (2018-02-01)

Comparative Analysis of International Databases of Adverse Drug Reactions
by: A. S. Kazakov, et al.
Published: (2020-09-01)

Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
by: Hilal A. Thaibah, et al.
Published: (2025-06-01)

Assessment of drug-related migraine in a real-world large-scale database
by: Fan Wu, et al.
Published: (2025-07-01)

Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-05-01)

Correction: Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system
by: Jiazhen Jiang, et al.
Published: (2025-06-01)

Optimisation of Approaches to Adverse Event Analysis in Bioequivalence Clinical Trials
by: A. B. Verveda, et al.
Published: (2024-04-01)

The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug
by: I. A. Lugovik, et al.
Published: (2025-06-01)

Levofloxacin: Analysis of Information on Adverse Reactions from Russian Spontaneous Report Database
by: S. K. Zyryanov, et al.
Published: (2020-05-01)

Major Aspects of Detection and Monitoring of Adverse Reactions Associated with Cephalosporin Antibiotic Treatment
by: E. Yu. Demchenkova, et al.
Published: (2021-03-01)

Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database
by: Lu Liu, et al.
Published: (2025-07-01)

Commentary: Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
by: Matthew Warren Brunke, et al.
Published: (2025-07-01)